Schizophrenia
📧 Sign up to get email alerts when something new happens for Schizophrenia.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2017-09-26FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Sun Pharmaceutical Industries, Inc.)
FDA approved a supplemental application for quetiapine fumarate from Sun Pharmaceutical Industries, Inc., approving updates to the generic's…
-
FDA approval · 2017-09-26FDA Approved: QUETIAPINE FUMARATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application to market a generic quetiapine fumarate product from Aurobindo Pharma Limited.
-
FDA approval · 2017-09-25FDA Approved: LATUDA — Supplemental Application (Sumitomo Pharma America, Inc.)
The FDA approved a supplemental application for LATUDA (lurasidone hydrochloride) from Sumitomo Pharma America, Inc., resulting in changes t…
-
CLINICAL_TRIALS trial_result · 2017-09-21Clinical Trial Update: Effects of Intranasal Oxytocin on Satiety Signaling in People With Schizophrenia [Phase 4]
Phase 4 trial evaluating intranasal oxytocin effects on satiety signaling in people with schizophrenia; results posted after completion.
-
CLINICAL_TRIALS trial_result · 2017-09-19Clinical Trial Update: Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine [EARLY_Phase 1]
Early-phase clinical trial evaluating D-cycloserine targeting a genetic mutation in glycine metabolism for schizophrenia and bipolar disorde…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-09-13Clinical Trial Update: Kuvan in People With Schizophrenia and Schizoaffective Disorder [Phase 1, Phase 2]
Clinical trial update for Kuvan investigating schizophrenia and schizoaffective disorder across Phase 1 and Phase 2, with completed status a…
-
CLINICAL_TRIALS research · 2017-09-11Clinical Trial Update: Work Activity Augmented by Cognitive Rehabilitation for Schizophrenia [Phase 2, Phase 3]
Phase 2/3 clinical trial evaluating work activity augmented by cognitive rehabilitation in schizophrenia and schizoaffective disorder.
-
FDA approval · 2017-09-08FDA Approved: RISPERIDONE — Supplemental Application (Ajanta Pharma USA Inc.)
FDA approved Ajanta Pharma USA Inc.'s supplemental application for risperidone, approving a new generic risperidone product.
-
CLINICAL_TRIALS trial_result · 2017-09-05Clinical Trial Update: Varenicline Effects In Schizophrenic Smokers [Phase 4]
A Phase 4 clinical trial evaluated varenicline effects in smokers with schizophrenia, with completed status and results posted in 2017.
-
CLINICAL_TRIALS trial_result · 2017-09-05Clinical Trial Update: L-arginine in Treatment as Usual in Schizophrenia [NA]
Clinical trial investigating L-arginine as an adjunct to treatment as usual in schizophrenia has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2017-08-31Clinical Trial Update: Psychosis-Associated Neuroinflammation in Schizophrenia
An update on a completed clinical trial from Universiteit Antwerpen investigating neuroinflammation associated with psychosis in schizophren…
-
CLINICAL_TRIALS trial_result · 2017-08-28Clinical Trial Update: Schizophrenia, Antipsychotic Treatment and the Risk for Diabetes Mellitus
This clinical trial update discusses a completed study examining whether antipsychotic treatment for schizophrenia and related conditions af…
-
CLINICAL_TRIALS trial_result · 2017-08-28Clinical Trial Update: Effects of Psychoeducation of Relatives to Patients With Serious Mental Illness [NA]
A completed clinical trial studied the effects of psychoeducation for relatives of patients with serious mental illness, including schizophr…
-
CLINICAL_TRIALS trial_result · 2017-08-25Clinical Trial Update: An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) [Phase 3]
The document reports the completion of an extension to a long-term safety study of ALKS 9072 (ALKS 9070) in schizophrenia, with results post…
-
CLINICAL_TRIALS trial_result · 2017-08-25Clinical Trial Update: Transcranial Direct Current Stimulation (tDCS) As A Treatment For Cigarette Craving and Cognitive Deficits in Schizophrenic [NA]
A completed clinical trial evaluated transcranial direct current stimulation (tDCS) for cigarette craving and cognitive deficits in individu…
-
CLINICAL_TRIALS trial_result · 2017-08-25Clinical Trial Update: Cognitive Behavioral Social Skills Training in Early Onset Psychosis [NA]
Clinical trial update on Cognitive Behavioral Social Skills Training for early onset psychosis, including schizophrenia, schizoaffective dis…
-
CLINICAL_TRIALS trial_result · 2017-08-17Clinical Trial Update: SPECT Study With SB-773812 In Schizophrenic Patients [Phase 1]
A Phase 1 SPECT imaging study of SB-773812 in schizophrenia patients was conducted by GlaxoSmithKline. The study status is completed.
-
CLINICAL_TRIALS research · 2017-08-17Clinical Trial Update: Individual Acceptance and Commitment Therapy (ACT) for Smoking Cessation for Schizophrenic Patients [NA]
Clinical trial evaluating Acceptance and Commitment Therapy (ACT) for smoking cessation in patients with schizophrenia; current trial status…
-
CLINICAL_TRIALS trial_result · 2017-08-16Clinical Trial Update: Schizophrenia Study In Adults [Phase 2]
A Phase 2 schizophrenia trial sponsored by GlaxoSmithKline has completed. The update notes the study status but does not provide results in …
-
FDA approval · 2017-08-11FDA Approved: INVEGA — Supplemental Application (Janssen Pharmaceuticals, Inc.)
The FDA approved Janssen's supplemental application for INVEGA (paliperidone), expanding its approved indications.
-
CLINICAL_TRIALS trial_result · 2017-08-10Clinical Trial Update: NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder [Phase 2]
Phase 2 trial update for NBI-98854 (valbenazine) in tardive dyskinesia in patients with schizophrenia or schizoaffective disorder; results w…
-
CLINICAL_TRIALS trial_result · 2017-08-08Clinical Trial Update: A Healthy Volunteer Study to Assess the Relative Bioavailability of 2 Forms of SB773812 Tablets. [Phase 1]
Phase 1 healthy-volunteer study comparing the relative bioavailability of two tablet forms of SB773812, sponsored by GlaxoSmithKline, in the…
-
CLINICAL_TRIALS trial_result · 2017-08-08Clinical Trial Update: tDCS to Enhance Cognitive Training in Schizophrenia [Phase 1, Phase 2]
Phase 1/2 trials evaluate whether transcranial direct current stimulation (tDCS) can enhance cognitive training in schizophrenia; the study …
-
CLINICAL_TRIALS trial_result · 2017-08-07Clinical Trial Update: Early Medication Discontinuation and Long-term Clinical Outcome in FEP
This completed trial update examines how early discontinuation of antipsychotic medication affects long-term outcomes in schizophrenia, incl…
-
FDA approval · 2017-08-04FDA Approved: ARIPIPRAZOLE — Supplemental Application (Quallent Pharmaceuticals Health LLC)
The FDA approved a supplemental application for aripiprazole by Quallent Pharmaceuticals Health LLC, bringing a generic version of the antip…